Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Computed Tomography | Case report

Talaromyces marneffei infection in a lung cancer patient: a rare case report

Authors: Fanhai Lin, Ye Qiu, Wen Zeng, Yi Liang, Jianquan Zhang

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Talaromyces marneffei is an invasive, and thermal dimorphic pathogenic fungus, whose infection is life threatening in human. Although immunocompromised patients, such as patients with human immunodeficiency virus infection and recipients of organ transplant, are susceptible hosts, infections have been recently reported in people with normal immune function. Patients with cancer may also be susceptible hosts but no case of T. marneffei infection has been reported in patients with lung cancer. In this case, we describe T. marneffei infection coexisting with primary pulmonary lymphoepithelioma-like carcinoma (LELC) in an HIV-negative patient.

Case presentation

A 50-year-old, previously healthy female presented with a 1-month history of cough and fever. CT scans showed a mass in the left lower lung, left pleural thickening, pleural effusion, and multiple swollen lymph nodes throughout the body. Based on the pathology of the left lung lesion, she was diagnosed with left primary pulmonary LELC complicated with T. marneffei. She received both anti-tumor and anti-fungal treatments. A subsequent CT re-examination demonstrated that the mass was absorbed remarkably after treatment. Follow up showed no tumor progression and no relapse of T. marneffei infection.

Conclusion

This case suggested that clinicians should pay more attention to the potential hosts of T. marneffei infection, especially those with lung cancer. Early diagnosis and treatment can improve the prognosis of T. marneffei infection coexisting with lung cancer.
Literature
1.
go back to reference Chan JF, Lau SK, Yuen KY. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg Microbes Infect. 2016;5:e19.PubMedPubMedCentral Chan JF, Lau SK, Yuen KY. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg Microbes Infect. 2016;5:e19.PubMedPubMedCentral
2.
go back to reference Joosten SA, Hannan L, Heroit G, Boerner E, Irving L. Penicillium marneffei presenting as an obstructing endobronchial lesion in an immunocompetent host. Eur Respir J. 2012;39:1540–3.CrossRef Joosten SA, Hannan L, Heroit G, Boerner E, Irving L. Penicillium marneffei presenting as an obstructing endobronchial lesion in an immunocompetent host. Eur Respir J. 2012;39:1540–3.CrossRef
3.
go back to reference Qiu Y, Lu D, Zhang J, Zhong X, Liu G, Li B. Treatment of disseminated Talaromyces marneffei with tracheal infection: two case reports. Mycopathologia. 2015;180:245–9.CrossRef Qiu Y, Lu D, Zhang J, Zhong X, Liu G, Li B. Treatment of disseminated Talaromyces marneffei with tracheal infection: two case reports. Mycopathologia. 2015;180:245–9.CrossRef
4.
go back to reference Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110.CrossRef Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110.CrossRef
5.
go back to reference Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin lnfect Dis. 1998;26:1107–10.CrossRef Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin lnfect Dis. 1998;26:1107–10.CrossRef
6.
go back to reference Lau SK, Lo GC, Lam CS, Chow WN, Ngan AH, Wu AK, et al. In vitro activity of posaconazole against Talaromyces marneffei by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin. Antimicrob Agents Chemother. 2017;61:e01480–16.CrossRef Lau SK, Lo GC, Lam CS, Chow WN, Ngan AH, Wu AK, et al. In vitro activity of posaconazole against Talaromyces marneffei by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin. Antimicrob Agents Chemother. 2017;61:e01480–16.CrossRef
7.
go back to reference Liang Y, Wang L, Zhu Y, Lin Y, Liu H, Rao H, et al. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer. 2012;118:4748–58.CrossRef Liang Y, Wang L, Zhu Y, Lin Y, Liu H, Rao H, et al. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer. 2012;118:4748–58.CrossRef
8.
go back to reference Fang S, Zhang M, Wei G, Lu KH. Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. Oncotarget. 2017;9:7175–81.PubMedPubMedCentral Fang S, Zhang M, Wei G, Lu KH. Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. Oncotarget. 2017;9:7175–81.PubMedPubMedCentral
Metadata
Title
Talaromyces marneffei infection in a lung cancer patient: a rare case report
Authors
Fanhai Lin
Ye Qiu
Wen Zeng
Yi Liang
Jianquan Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-3968-5

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue